Lyu Jingya, Imachi Hitomi, Fukunaga Kensaku, Yoshimoto Takuo, Zhang Huanxiang, Murao Koji
Jingya Lyu, Hitomi Imachi, Kensaku Fukunaga, Takuo Yoshimoto, Koji Murao, Department of Endocrinology and Metabolism, Faculty of Medicine, Kagawa University, Kagawa 761-0793, Japan.
World J Hepatol. 2015 Oct 28;7(24):2535-42. doi: 10.4254/wjh.v7.i24.2535.
Infection by hepatitis C virus (HCV), a plus-stranded RNA virus that can cause cirrhosis and hepatocellular carcinoma, is one of the major health problems in the world. HCV infection is considered as a multi-step complex process and correlated with abnormal metabolism of lipoprotein. In addition, virus attacks hepatocytes by the initial attaching viral envelop glycoprotein E1/E2 to receptors of lipoproteins on host cells. With the development of HCV model system, mechanisms of HCV cell entry through lipoprotein uptake and its receptor have been extensively studied in detail. Here we summarize recent knowledge about the role of lipoprotein receptors, scavenger receptor class B type I and low-density lipoprotein receptor in the entry of HCV, providing a foundation of novel targeting therapeutic tools against HCV infection.
丙型肝炎病毒（HCV）是一种正链RNA病毒，可导致肝硬化和肝细胞癌，其感染是全球主要的健康问题之一。HCV感染被认为是一个多步骤的复杂过程，且与脂蛋白代谢异常相关。此外，病毒通过最初将病毒包膜糖蛋白E1/E2附着于宿主细胞上脂蛋白的受体来攻击肝细胞。随着HCV模型系统的发展，HCV通过脂蛋白摄取及其受体进入细胞的机制已得到广泛深入研究。在此，我们总结了脂蛋白受体、B类清道夫受体I型和低密度脂蛋白受体在HCV进入过程中作用的最新知识，为针对HCV感染的新型靶向治疗工具奠定基础。
